Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

NCT03858972 is registered in ClinicalTrials.gov with Odonate Therapeutics, Inc. as lead sponsor.

NCT NCT03858972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03858972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
Lead sponsor
Odonate Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 5, 2019
Completion date
June 11, 2021
Enrollment
152 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer